|Bid||54.50 x 17000|
|Ask||56.50 x 16200|
|Day's Range||53.00 - 53.00|
|52 Week Range||46.20 - 60.00|
|Beta (5Y Monthly)||0.18|
|PE Ratio (TTM)||32.38|
|Forward Dividend & Yield||1.58 (2.89%)|
|Ex-Dividend Date||Mar 03, 2022|
|1y Target Est||N/A|
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that two abstracts have been accepted for poster presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, scheduled for May 16 - May 19, 2022, in Washington, DC. The presentations will highlight preclinical data characterizing two investigationa
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
Australia Sunny Glass Group Limited (NSX:AG1) advises that it has commenced preparations to make an application for admission to the Official List of the Australian Securities Exchange and proposes to undertake a public offer to raise additional capital in support of its application.